# What the growth hormone–releasing hormone receptor can tell us

- Article ID: research-063
- Product: CJC-1295 No DAC (cjc-1295-no-dac-623, cjc-1295-no-dac-520, cjc-1295-no-dac-609)
- Canonical page: https://heritagebiolabs.com/research-library/articles/063-what-the-growth-hormonereleasing-hormone-receptor-can-tell-us
- Product collection: https://heritagebiolabs.com/research-library/products/cjc-1295-no-dac
- Product page: https://heritagebiolabs.com/product/cjc-1295-no-dac-623
- Product page: https://heritagebiolabs.com/product/cjc-1295-no-dac-520
- Product page: https://heritagebiolabs.com/product/cjc-1295-no-dac-609
- Reading focus: Interpreting evidence (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2020, 2024

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Short amino-acid chains joined by peptide bonds are called peptides. When their shape and chemistry fit a receptor on a cell, they can pass along a biological signal. CJC-1295 No DAC commonly refers to Mod GRF (1–29), a synthetic 29-residue relative of growth hormone–releasing hormone (GHRH) with four substitutions. Its design raises a specific question about how the original hormone engages its receptor. [1]

A 2020 laboratory study used cryo-electron microscopy, a technique for imaging molecules held at very low temperatures, to examine the human GHRH receptor. Researchers looked at the receptor bound to the natural hormone and to a G protein that relays the signal inside the cell. The image showed the hormone making numerous contacts as it interacted with the receptor. The hormone's starting end participated in a particularly extensive network of contacts. [2]

The study helps explain why replacing a residue in a short hormone can matter. A change near the beginning may affect a contact in the binding site, while a change elsewhere may influence the shape the peptide takes in that site. A structural image can point to where those effects might occur. Researchers would still need to test the engineered sequence directly to learn how strongly it activates the receptor and which cellular responses it produces. [1, 2]

No recent primary receptor study of the exact no-DAC compound was identified. The 2020 work is an older, closely related experiment using the natural ligand. Its image describes a human receptor assembled in the laboratory. The study did not measure hormone release in a person, and the FDA's separate assessment did not identify clinical studies of the specific no-DAC form. [1, 2]

## Sources

1. U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting. FDA briefing document on CJC-1295-related bulk drug substances (publication 2024-12-04). <https://www.fda.gov/media/183819/download>
2. Zhou F et al. Structural basis for activation of the growth hormone-releasing hormone receptor. Nature Communications (publication 2020-10-15). <https://pubmed.ncbi.nlm.nih.gov/33060564/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 013 - Cagrilintide and CJC-1295 No DAC.docx; article 63; content SHA-256 56c9b59baafd9932fc464d48f945e1faca52957a272f86727641b40a6d7aae0c.
